Interstitial lung disease due to savolitinib
10.3760/cma.j.cn114015-20241010-00084
- VernacularTitle:赛沃替尼致间质性肺炎
- Author:
Rui QIU
1
;
Mingying LUO
;
Gaofeng ZHENG
;
Jinlan LI
Author Information
1. 四川省简阳市人民医院药学部，简阳 641400
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Lung diseases, interstitial;
Savolitinib
- From:
Adverse Drug Reactions Journal
2025;27(6):377-379
- CountryChina
- Language:Chinese
-
Abstract:
A 77-year-old male patient with lung adenocarcinoma received targeted therapy with savolitinib 400 mg orally once daily. Eleven days later, he developed fever and chest CT scan revealed interstitial changes in both lungs, which were improved after savolitinib withdrawal and glucocorticoids treatment. The patient was given the same dose of savolitinib orally again. Three days later, the patient′s cough and shortness of breath worsened. Laboratory tests showed percentage of neutrophils 90% and procalcitonin 1.56 μg/L. Chest CT scan indicated interstitial changes in the right lung. The patient was diagnosed with interstitial pneumonia companied with infection, which was considered to be related to savolitinib. Savolitinib was discontinued and glucocorticoids and anti-infective therapy were given. After 14 days, the patient′s cough and shortness of breath were improved, laboratory tests showed percentage of neutrophils 89% and procalcitonin 0.18 μg/L.
